Johnson & Johnson (JNJ)

JNJ (NYSE:Drugs) EQUITY
$122.73
pos +0.00
+0.00%
Today's Range: 120.90 - 122.74 | JNJ Avg Daily Volume: 6,957,600
Last Update: 02/24/17 - 4:00 PM EST
Volume: 0
YTD Performance: 5.63%
Open: $0.00
Previous Close: $120.90
52 Week Range: $105.04 - $126.07
Oustanding Shares: 2,720,531,728
Market Cap: 331,088,711,298
6-Month Chart
TheStreet Ratings Grade for JNJ
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 7 7 8
Moderate Buy 2 2 2 2
Hold 10 9 9 8
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
Mean Rec. 2.37 2.26 2.26 2.16
Latest Dividend: 0.80
Latest Dividend Yield: 2.63%
Dividend Ex-Date: 02/24/17
Price Earnings Ratio: 20.52
Price Earnings Comparisons:
JNJ Sector Avg. S&P 500
20.52 20.50 30.70
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
7.63% 17.92% 32.98%
GROWTH 12 Mo 3 Yr CAGR
Revenue -5.70 0.00 0.00
Net Income 7.30 0.20 0.06
EPS 8.30 0.20 0.07
Earnings for JNJ:
EBITDA 21.17B
Revenue 71.89B
Average Earnings Estimates
Qtr (03/17) Qtr (06/17) FY (12/17) FY (12/18)
Average Estimate $1.76 $1.79 $7.02 $7.42
Number of Analysts 9 8 10 10
High Estimate $1.80 $1.83 $7.14 $7.80
Low Estimate $1.71 $1.67 $6.95 $7.22
Prior Year $1.68 $1.74 $6.73 $7.02
Growth Rate (Year over Year) 4.83% 2.73% 4.35% 5.70%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
It's better to be early than wrong. Though being wrong isn't so awful.
Icahn may have a tough time finding interest in this behemoth.

Takeaways and Observations Real Money Pro($)

 
You might want to review your holdings in the sector.

Biotech Buoyed by Deal Talk Real Money Pro($)

M&A activity is in a serious upswing, and here are some names to watch.
Amazon, J&J, IBM and others don't deserve this treatment.
They have become a referendum on Trump's plans for lower corporate taxes.
M&A, drug approvals and Trump are all on my watch list.
The Actelion buyout opens the way for other deals.
The Actelion buyout opens the way for other deals.

Columnist Conversations

One of the fundamental concepts of market characteristics is they generally don't go straight up or straight d...
With less than an hour left in the session COP is trading below its January low. This key support area($47.20)...
tremendous flow here today and a big reversal candle. BOUGHT LB MAY 50 CALL AT 3.80 Poor reaction pos...
We have a nice gainer here, let's unload it SOLD OLED MAR 75 CALL AT 6.40 (in at 2.70)

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.